Clinical observation on palliative treatment of intractable end-stage cancer pain by subcutaneous infusion of morphine and hydromorphone

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059678

Enrollment

Unknown

Registered

2022-05-06

Start date

2021-08-31

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

Morphine group:Subcutaneous infusion of morphine

Hydromorphone group:Subcutaneous infusion of hydromorphone

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old with end-stage tumors 2. Patients were dissatisfied with pain control when the oral dose of morphine exceeded 100mg/d and VAS scores > 5 points; 3. Voluntarily participate in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The general condition is very poor and cannot tolerate treatment; 2. Unable to actively cooperate; Unable to objectively describe symptoms; 3. Allergic to morphine and hydromorphone; 4. Patients with consciousness disorder or other diseases who cannot correctly complete the pain score and other scoring tables; 5. Patients who cannot be followed up on schedule.

Design outcomes

Primary

Measure	Time frame
VAS scores;	—

Secondary

Measure	Time frame
SF-36;Adverse reactions;Analgesic drug dosage;Survival rate at each time point;	—

Countries

china

Contacts

Public ContactWan Chengfu

The First Affiliated Hospital of China Medical University

doctor_wanty@163.com+86 13704026541

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026